Press release
ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer
ISOThrive Inc. announced promising Phase 2 interim data for ISOT-101, a novel NERD treatment for PPI partial-responders. Pharma veteran Mike Walther joins as Chief Strategy Officer, accelerating strategic opportunities. This positions ISOThrive for high-value transactions in a multi-billion-dollar market.ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need.
Image: https://www.globalnewslines.com/uploads/2025/07/5b4b64d3d25a93a3b2f4f1dadf688558.jpg
These positive developments highlight the significant market potential of ISOT-101 in the NERD PPI-PR segment, an estimated 15-30 million patients in the U.S alone who are inadequately addressed by current gold standard therapies and a multi-billion-dollar annual company market opportunity.
In light of this clinical and commercial potential, long-time ISOThrive board member and pharmaceutical industry veteran Mike Walther will expand his role as Chief Strategy Officer. Mr. Walther's 30+ year gastroenterology experience, including the launch of and key leadership roles on blockbuster heartburn medications, Prevacid Registered and Dexilant Registered , will be leveraged to accelerate the company's next stage opportunities, including strategic partnerships and/or M&A.
"This encouraging interim data supports our novel approach and strengthens our development program," said Jack Oswald, CEO. "Our treatment shows the potential to become a leading solution for millions of NERD patients who remain symptomatic despite current treatment options. We believe this progress positions us for a high-value strategic transaction. Bringing a seasoned executive like Mike Walther on board is a critical step in capitalizing on this momentum."
Mike Walther, Chief Strategy Officer, added, "The interim data for ISOT-101 is exceptionally encouraging, suggesting a meaningful impact in a patient population that remains symptomatic with current options. Having been involved with two of the most successful PPIs, I am thrilled to now work even more closely with the executive team at this pivotal moment to help realize the immense potential of this product and accelerate our path forward for a non-acid suppressing, first-of-it's kind microbiome-targeting therapy ."
Study completion scheduled for Q4 2025.
ISOThrive Inc. is developing novel, microbiome-targeted therapeutics for gastrointestinal diseases. Its lead product, ISOT-101, with over 30 global patents, is a first-in-class treatment being evaluated for Non-Erosive Reflux Disease (NERD). ISOThrive.com
Acid Reducing Medications: Omeprazole (Prilosec Registered : AstraZeneca Procter&Gamble, Zegerid Registered : Riley), Esomeprazole (Nexium Registered : AstraZeneca), Lansoprazole (Prevacid Registered : Takeda), Dexlansoprazole (Dexilant Registered : Takeda), Pantoprazole (Protonix Registered : Pfizer), Rabeprazole (Aciphex Registered : Waylis), Vonoprazan (Voquezna Registered : Phathom).
Media Contact
Company Name: ISOThrive Inc
Contact Person: Jack Oswald
Email: Send Email [http://www.universalpressrelease.com/?pr=isothrive-announces-promising-phase-2-interim-data-for-novel-heartburn-treatment-and-appoints-pharma-veteran-mike-walther-as-chief-strategy-officer]
Phone: 415-272-6200
Address:2165 Toyon Drive
City: Healdsburg
State: CA
Country: United States
Website: http://ISOThrive.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer here
News-ID: 4088712 • Views: …
More Releases from Getnews

Best GLP-1 App for 2025: MeAgain Takes Top Position
MeAgain has been recognized as the #1 GLP-1 app in the market, supporting users on medications like Zepbound, Mounjaro, Wegovy, Ozempic, and compounded versions such as Tirzepatide and Semaglutide. The platform offers comprehensive tracking including injection reminders, side effect management, nutrition tracking, and an AI coach for personalized support. Users praise its all-in-one approach: "I used to juggle 4 different apps. This one app now does it all," says user…

Springville Freedom Credit Union Expands Auto and RV Loan Services to Better Ser …
Image: https://www.globalnewslines.com/uploads/2025/09/1759164728.jpg
Springville Freedom Credit Union has announced expanded offerings designed to make vehicle ownership more accessible and affordable for the community. With a commitment to providing flexible financial solutions, the credit union now offers specialized loan programs to meet the growing demand for reliable transportation and recreational financing.
One of the newest offerings includes a New Car Loan Springville [https://www.google.com/maps?cid=7057362679886001310] program, designed to help individuals drive away in the latest models…

PushAds.net Launches New AI-Driven Toolkit to Boost Ad Campaign ROI and Targetin …
Image: https://www.globalnewslines.com/uploads/2025/09/1758887006.jpg
Image by FatAds
Platform enhances Smart Bidding, adds Granular Targeting and In-Page Push to address demands for quality and efficiency in push traffic.
LIMASSOL, Cyprus - PushAds.net, a rapidly expanding push notification advertising platform, today announced a significant upgrade to its technological infrastructure. The update introduces a new suite of targeting and optimization tools designed to deliver higher Click-Through Rates (CTR) and a superior Return on Investment (ROI) for marketers, affiliates,…

Producer/ Director Dale Fabrigar Unleashes Very Frightening Tales Part 2 - Comin …
Image: https://www.globalnewslines.com/uploads/2025/09/1759088649.jpg
Very Frightening Tales 2 | A Horror Anthology
Following the success of the chilling anthology Very Frightening Tales, which was picked up by Indian streamer JioStar (aka Disney Star), acclaimed producer/director Dale Fabrigar (D-Railed, They Crawl Beneath) returns with the next terrifying installment: Very Frightening Tales 2.
Los Angeles, CA - September 29, 2025 - Following the success of the chilling anthology Very Frightening Tales , which was picked up by…
More Releases for ISOThrive
Animal Microbiome Market Latest Trends and Growth Factors Analysis 2024 to 2031
Animal Microbiome Market worth $12.4 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd.'s recently published report, "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030," provides an in-depth analysis and comprehensive study of the market, examining its key factors.
Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1046
According to the most recent market intelligence research report by InsightAce…
Functional Dyspepsia Market Size is Set for Rapid Growth as Innovative Treatment …
The Functional Dyspepsia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer
[Nevada, United States] - DelveInsight's "Functional Dyspepsia Market Insights,…
Functional Dyspepsia Market Forecasts by DelveInsight Signal Groundbreaking Grow …
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Functional Dyspepsia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Functional Dyspepsia therapies, and current & forecasted…
Animal Microbiome Market Survey Detailed Analysis and Forecast 2023-2031
The newly published report titled "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030." of InsightAce Analytic Pvt. Ltd. features in-depth analysis and an extensive study on the market, exploring its significant factors.
The Animal Microbiome Market Size is valued at 6241.41 Million in 2022 and is predicted to reach 13687.71 Million by the year 2031 at a 9.2 % CAGR during the forecast…
Dyspepsia Market to Grow Rapidly During the Forecast Period (2019-2032) -DelveIn …
DelveInsight's Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Dyspepsia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Dyspepsia Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to…
Human Microbiome Modulators Market Analysis By Type, Application, Growth, Demand …
Worldwide Human Microbiome Modulators Market 2022 Research Report presents a professional and complete analysis of the Global Human Microbiome Modulators Market on the current situation. This report includes development plans and policies along with Human Microbiome Modulators manufacturing processes and price structures. the reports 2022 research report offers an analytical view of the industry by studying different factors like Human Microbiome Modulators Market growth, consumption volume, Market Size, Revenue,…